This company has shut down. Tome Biosciences is no longer operating — its last tracked round was a Series A in 2023.
Explore the Startup GraveyardTome Biosciences is a biotechnology company that develops programmable gene insertion technology.
Tome Biosciences has raised $213.0M in total funding. The most recent round was Series A. The last funding was announced in December 2023.
Tome Biosciences's investors include Andreessen Horowitz, ARCH Venture Partners, Polaris Partners, Longwood Fund, Bruker.
Tome Biosciences is headquartered in Watertown, United States.
Tome Biosciences is a biotechnology company that develops programmable gene insertion technology.
Tome Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tome Biosciences — Funding & Investors." VCBacked, December 12, 2023, https://www.vcbacked.co/company/tome-biosciences. Accessed July 20, 2026.
VCBacked. (2023). Tome Biosciences — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/tome-biosciences
{{cite web |title=Tome Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/tome-biosciences |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated